Background/Objective: We reported that 43% of patients with Lambert-Eaton myasthenic syndrome (LEMS) and small cell lung cancer (SCLC) had an antibody called anti-glial nuclear antibody (AGNA), defined by the immunoreaction with the nuclei of the Bergmann glia of the cerebellum. This study was undertaken to identify the antigen recognized by AGNA and to confirm the association with paraneoplastic LEMS in a larger series.
The Lambert-Eaton myasthenic syndrome (LEMS) is a disorder of neuromuscular transmission mediated by voltage-gated calcium channel (VGCC) antibodies. 1 Cancer, almost always small cell lung carcinoma (SCLC), is detected in up to 50% of patients with LEMS. 1 Presently, there are no biologic markers that predict which LEMS patients are paraneoplastic. In a previous study, we found that 43% of patients with LEMS and SCLC had an antibody, called anti-glial nuclear antibody (AGNA), defined by the immunoreaction with the nuclei of the Bergmann glia of the cerebellum. 2 We observed a robust association between AGNA and SCLC. The frequency of AGNA was found higher than expected, for the simple presence of SCLC, in paraneoplastic LEMS. 2 Because we observed that AGNA reactivity was widely expressed in the developing nervous system, 2 we screened a fetal brain library with AGNA-positive sera and identified the AGNA antigen as SOX1, a protein implicated in neural development and expressed in SCLC. 3, 4 We also analyzed a larger series of LEMS to confirm that antibodies against SOX1 are restricted to LEMS with SCLC. METHODS Sera. The serum of 105 patients with LEMS (55 with SCLC, 50 idiopathic) was ascertained from a nationwide Dutch study (67 patients) 5 and from 38 Spanish patients sent to our laboratory to detect antineuronal or VGCC antibodies. All patients presented clinical symptoms and neurophysiologic studies compatible with the diagnosis of LEMS. All sera were positive for VGCC antibodies, except six LEMS patients without a tumor and one with a SCLC. The latter was tested after chemotherapy during clinical remission. Paraneoplastic LEMS required the histologic confirmation of cancer. LEMS was considered idiopathic when no tumor was diagnosed after a follow-up of at least 3 years after the diagnosis of LEMS and serum was negative for paraneoplastic (Hu, CV2, Ri, amphiphysin, ANNA3, PCA2) antibodies usually associated with SCLC. 1, 6 An additional LEMS patient could not be included in any group. He was a male patient and a lifelong smoker, who developed LEMS and cerebellar ataxia at age 62 and died at age 76 from stroke. Low titer of Hu antibodies was present in the serum, but cancer was never diagnosed. The presence of Hu antibodies would have indicated a definite paraneoplastic LEMS according to recent guidelines on paraneoplastic neurologic syndromes. 6 However, in the current study, we also required the histologic diagnosis of SCLC to define LEMS as paraneoplastic so the patient was not included in the paraneoplastic group. As controls, we analyzed the serum of 50 patients with SCLC without neurologic symptoms and 50 patients with paraneoplastic neurologic syndromes, SCLC, and Hu antibodies (sensory neuropathy 27, cerebellar degeneration 9, limbic encephalitis 6, encephalomyelitis 4, sensorimotor neuropathy 3, brainstem encephalitis 1). The presence of AGNA seropositivity was defined by the staining of the nuclei of Bergmann glia in standard immunohistochemistry of rat cerebellum (figure 1). 2 Isolation of cDNA clones and detection of SOX1 antibodies. A Uni-ZAP XR Library (Stratagene, La Jolla, CA) from human fetal brain was immunoscreened with a pool of four AGNA-positive sera (each diluted 1:1,000) as previously reported. 7 Phage-positive clones were subcloned in pBluescript using the in vivo excision phage rescue protocol (Stratagene) and sequenced.
The presence of SOX1 antibodies in patient's sera was examined using nitrocellulose filters with mixed phage plaques (50% of plaques from positive clones and 50% from irrelevant clones). Filters were cut into four pieces, each one incubated with different patient's sera (dilution 1:1,000), and developed by an avidin biotin immunoperoxidase technique as described. 7 Filters were scored by two investigators blind to the clinical diagnosis. To confirm the results obtained with our SOX1 clone (clone 1), the same analysis was repeated with another SOX1 clone (clone 2) previously obtained by screening the SCLC line NCI-H740 with a pool of five sera from SCLC patients without paraneoplastic neurologic disorders. 4 Clone 2 contained the SOX1 cDNA segment 192 to 2,261 of Y13436.1 GenBank accession number. 4, 8 Affinity purification of antibodies. Filters with purified phage plaques expressing SOX1 or irrelevant Escherichia coli proteins were incubated with AGNA or control serum (dilution 1:200) for 12 hours at 4°C. After incubation, the serum without the IgG bound to the phage plaques was collected. Filters were washed extensively and bound antibodies were eluted with sodium citrate (pH 2.5) and neutralized with Tris (pH 8.8). Purified antibodies were concentrated with a Centricon Plus-20 centrifugal filter (Millipore, Billerica, MA) and the IgG measured by nephelometry. 9 The eluted antibodies and the serum collected after the incubation were probed by immunohistochemistry on rat cerebellar sections to see if they reproduced the AGNA immunoreactivity.
RESULTS
Screening of the cerebellar expression library resulted in the isolation of one clone (clone 1) identical to the human SOX1 gene (Gen-Bank accession no. NM_005986.2) spanning 2,952 nucleotides. The clone lacked 207 bp at the 5= end and contained an internal deletion of 65 bp within 898-693 of NM_005986.2. This deletion was not present in the SOX1 clone (clone 2) previously described. 4 (figure e-1 on the Neurology Web site; www.neurology.org). The predicted translation of clone 1 had 230 amino acids identical to SOX1 protein (GenBank accession no. NP_005977.2). Although the clone lacked the first 49 amino acids of the N-terminal end of SOX1 protein, it contained the full DNA-binding domain known as HMG-box. 10 The internal deletion caused an out-of-frame translation of 158 amino acids of the C-terminal with no significant homologies in the databases (figure e-2). Because SOX1 plaques were recognized by all the four AGNA sera used in the screening and because SOX1 is expressed in the Bergmann glia of adult cerebellum, 11 we pursued further studies with this protein. To ensure the specificity of the antibody recognition, IgG was eluted from purified phage plaques expressing the SOX1 protein and incubated with AGNApositive serum. AGNA immunoreactivity was reproduced when tested by immunohistochemistry on rat cerebellum (figure 1). In contrast, the serum collected after incubation with the phage plaques expressing the SOX1 protein failed to reproduce the AGNA labeling (not shown), suggesting that only the antibodies that bind with the SOX1 protein were responsible for the AGNA immunoreactivity.
Filters with plaques containing SOX1 protein of clone 1 reacted with the serum of 29 of 55 (52%; 95 CI: 39 to 65%) paraneoplastic and 0 of 50 idiopathic LEMS patients (p Ͻ 0.0001) (figure 2). The second SOX1 clone (clone 2), 4,8 without the internal deletion, identified six additional sera (35/55)from paraneoplastic LEMS patients. Thus, the frequency of SOX1 antibodies was 64% (95 CI: 48 to 75%) in paraneoplastic and 0% in idiopathic LEMS (p Ͻ 0.0001). The additional LEMS patient with low titer of Hu antibodies, but no cancer was positive for SOX1 antibodies.
Compared with paraneoplastic LEMS, patients with other paraneoplastic neurologic syndromes, SCLC, and Hu antibodies had a lower frequency of SOX1 antibodies (16/50; 32%; 95 CI: 19 to 46%), (p ϭ 0.002) using the clone 2 as antigen in the assay. Positive paraneoplastic cases included 10 with sensory neuropathy, 3 with cerebellar degeneration, 2 with encephalomyelitis, and 1 with limbic encephalitis. The frequency of SOX1 antibodies in patients with isolated SCLC was 22% (95 CI: 13 to 35%) (table).
As expected from previous studies with other antibodies, 12 the immunoblot assay to detect SOX1 antibodies was more sensitive than the detection of AGNA by immunohistochemistry. SOX1 antibodies were identified in all 26 paraneoplastic LEMS sera with positive AGNA immunoreactivity but also in 10 of the 29 (34%) paraneoplastic LEMS sera that were AGNA negative or inconclusive due to the presence of concomitant anti-nuclear antibodies that prevented the immunohistochemical diagnosis of AGNA. 2 DISCUSSION This study identified SOX1 as the antigen recognized by AGNA and showed that in patients with LEMS, SOX1 antibodies can specifically the presence of an underlying SCLC. SOX1 belongs to a large family of developmental transcription factors that share a highly conserved DNA-binding domain known as the HMG-box, defined by 79 amino acids. 3 The human SOX gene family is classified in groups from A to H. SOX1 belongs to group B1 along with SOX2 and SOX3. 13 SOXB1 genes are strongly expressed in the early neuroectoderm and the developing nervous system. 14 In the adult nervous system, SOXB1 genes are down-regulated but remain active in adult neural stem cells and selected groups of differentiated neurons. 13 SOX1 and SOX2 are preferentially expressed in the Bergmann glia in the adult cerebellum, 11 in concor-
Figure 2
Detection of SOX1 antibodies with phage plaques (see Methods)
Filters were cut into four pieces and used to screen patient's sera. The right lower quadrant was incubated with normal human serum and the others with three different anti-glial nuclear antibody-positive sera. dance with the immunoreactivity observed with AGNA. 2 A previous serologic analysis of cDNA expression libraries (SEREX) derived from SCLC cell lines screened with sera from SCLC patients without neurologic disorders isolated SOXB1 genes confirming that the encoded proteins are expressed in SCLC and are highly immunogenic. 4 Antibodies against SOXB1 proteins were present in 28% of a series of 90 patients with SCLC without neurologic disorders. 8 All patients with SOX2 and SOX3 antibodies were also seropositive for SOX1 and only five patients had SOX1 but no SOX2 or SOX3 antibodies. 8 The common reactivity of the antibodies against all three SOXB1 proteins suggests that the immunoreactivity of SCLC patient sera is directed against epitopes of the conserved HGM box. 4 Although we did not analyze the presence of SOX2 and SOX3 antibodies in our series, the previous data suggest that detection of SOX1 antibodies is the best approach to identify the immunoreactivity of the patient's serum against SOXB1 proteins.
This study confirms for the first time that immunity against SOX1 is present in patients with paraneoplastic LEMS while being absent in patients with nonparaneoplastic LEMS, suggesting that the SCLC is seminal in the development of the immune response. Unlike SCLC patients with VGCC antibodies, we did not find an increased frequency of SOX1 antibodies in patients with Hu-associated paraneoplastic neurologic syndromes and SCLC. In fact, the frequency of SOX1 antibodies in patients with Hu-associated paraneoplastic neurologic syndrome and SCLC (32%) was not significantly different from that found in the patients with isolated SCLC (22%) in line with the previously reported frequency (28%) using the same clone (clone 2) as antigen. 8 These observations could indicate that the individual variables that help to mount an immune response against the VGCC of SCLC are also relevant in raising a SOX1-mediated anti-tumor response.
In a previous study, we found AGNA in two patients with limbic encephalitis, SCLC and voltage-gated potassium channel (VGKC) antibodies. 15 No AGNA reactivity was found in patients with limbic encephalitis, SCLC, and absence of VGKC antibodies or those with nonparaneoplastic limbic encephalitis and high titers of VGKC antibodies. 16, 17 As in the current work, we have confirmed that AGNA immunoreactivity in patients with limbic encephalitis is caused by SOX1 antibodies (unpublished). Taken together, these data suggest that, in the setting of a SCLC, there is a close association between the presence of SOX1 antibodies and antibodies against neuronal membrane channels that will require further studies.
When neurologists evaluate a patient with LEMS, there are no robust clues that predict the presence of an underlying cancer. Paraneoplastic neuronal or muscle antibodies are reported in up to 37% of patients with paraneoplastic LEMS, but their predictive value remains unclear. 18 In a previous study, we found that the absence of human leukocyte antigen B8 and a positive smoking history to be highly sensitive (88 and 96%) for the presence of SCLC albeit with low specificity (Ͻ70%). 5, 19 We demonstrate that the detection of SOX1 antibodies was restricted to LEMS patients with histologically proven SCLC, with one exception. The clinical profile of this particular patient suggests that the tumor might have been subdued by the immune response as reported previously. 20 In conclusion, the detection of SOX1 antibodies is a simple test that may be used to define a better model to predict the presence of SCLC in LEMS patients.
